Incyte Dividend yield




   USD/share 
 Price  68.78
 Dividend  0.00
 Earnings  -1.25
 Cash-flow  0.00
 Book value  11.86
 Equity  11.90

Incyte is part of Pharmaceuticals and Biotechnology business, which is part of Health Care industry. Incyte is a company from USA, and his stocks are publicly traded.

Incyte paid a total dividend of 0 million USD last year, for a market value of 15,132 millions (Market Cap 12,676 millions). Dividend per share of Incyte is 0.00 USD, and his stock market price 68.78 USD.

According to the chart below where dividend yield is displayed, Incyte, has a dividend yield of 0%, amount in contrast with the positive dividend offered by both the market average and companies from USA, Health Care industry, and Pharmaceuticals and Biotechnology sector. This lack of dividends of Incyte might harm the evolution of share price if the company is not clearly expanding his business.

In addition, you should compare Incyte dividend yield with other Pharmaceuticals and Biotechnology companies or firms from USA.

Dividend yield of Incyte

Incyte Dividend Payout

About the ability of Incyte to maintain his current dividend of USD 0.00 per share, an amount that accounts for 0.00%, we should study its payout ratio both on earnings and on cash-flows (see chart below). Incyte payout on ernings is currently 0.00%, which is lower than the market average and companies in his industry and sector.

The following figure shows payout ratios over earnings and cashflow of Incyte, compared againt world market average, USA companies, Health Care industry and Pharmaceuticals and Biotechnology sector companies.

Incyte payout

Incyte Dividend History

Year Yield  USD  Paypout  Shares* 
Present0.00%0.000.00%220
20200.00%0.000.00%217
20190.00%0.000.00%214
20180.00%0.000.00%212
20170.00%0.000.00%211
20160.00%0.000.00%188
20150.00%0.000.00%179

*In millions

Incyte Stock performance

Finally, last moth Incyte showed a return of -10.10% compared to a worldwide -1.33% average, and a -3.33% of Health Care firms. Over the last year, the company obtained a -23.40% versus a worldwide performance of a 31.58%. More detailed information can be seen in the following graph for USA and Pharmaceuticals and Biotechnology firms.

Incyte stock and market return